KR20230084166A - Ox40 관련 질환을 치료하는 방법 - Google Patents
Ox40 관련 질환을 치료하는 방법 Download PDFInfo
- Publication number
- KR20230084166A KR20230084166A KR1020237011786A KR20237011786A KR20230084166A KR 20230084166 A KR20230084166 A KR 20230084166A KR 1020237011786 A KR1020237011786 A KR 1020237011786A KR 20237011786 A KR20237011786 A KR 20237011786A KR 20230084166 A KR20230084166 A KR 20230084166A
- Authority
- KR
- South Korea
- Prior art keywords
- weeks
- antibody
- administration
- ser
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089809P | 2020-10-09 | 2020-10-09 | |
| US63/089,809 | 2020-10-09 | ||
| US202063116365P | 2020-11-20 | 2020-11-20 | |
| US63/116,365 | 2020-11-20 | ||
| US202163233592P | 2021-08-16 | 2021-08-16 | |
| US63/233,592 | 2021-08-16 | ||
| PCT/JP2021/037481 WO2022075476A1 (en) | 2020-10-09 | 2021-10-08 | Method for treating ox40 related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230084166A true KR20230084166A (ko) | 2023-06-12 |
Family
ID=81126528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237011786A Withdrawn KR20230084166A (ko) | 2020-10-09 | 2021-10-08 | Ox40 관련 질환을 치료하는 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230383001A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4225371A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545084A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230084166A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116437955A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021358274A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198414A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301935A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004113A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202222343A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022075476A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| IL326123A (en) * | 2023-07-25 | 2026-03-01 | Inmagene Pte Ltd | Methods of treating alopecia areata and atopic dermatitis |
| WO2025244002A1 (ja) * | 2024-05-21 | 2025-11-27 | 国立大学法人京都大学 | ベンダムスチンによるt細胞の減少を抑制するために使用されるt細胞減少抑制剤 |
| WO2025259719A1 (en) * | 2024-06-10 | 2025-12-18 | Walden Biosciences, Inc. | Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease |
| WO2026145427A1 (en) * | 2024-12-30 | 2026-07-09 | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. | Bispecific antibodies targeting ox40 and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196359A1 (en) | 2005-11-25 | 2010-08-05 | Shinichiro Kato | Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same |
| WO2019229155A1 (en) | 2018-05-31 | 2019-12-05 | Glenmark Pharmceuticals S.A. | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
| US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| RU2759630C2 (ru) * | 2016-09-22 | 2021-11-16 | Ридженерон Фармасьютикалз, Инк. | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r |
| TWI787203B (zh) * | 2016-09-23 | 2022-12-21 | 美商建南德克公司 | Il-13拮抗劑用於治療異位性皮炎之用途 |
-
2021
- 2021-10-08 KR KR1020237011786A patent/KR20230084166A/ko not_active Withdrawn
- 2021-10-08 US US18/248,238 patent/US20230383001A1/en active Pending
- 2021-10-08 IL IL301935A patent/IL301935A/en unknown
- 2021-10-08 TW TW110137584A patent/TW202222343A/zh unknown
- 2021-10-08 CN CN202180068736.0A patent/CN116437955A/zh active Pending
- 2021-10-08 CA CA3198414A patent/CA3198414A1/en active Pending
- 2021-10-08 MX MX2023004113A patent/MX2023004113A/es unknown
- 2021-10-08 WO PCT/JP2021/037481 patent/WO2022075476A1/en not_active Ceased
- 2021-10-08 EP EP21877775.3A patent/EP4225371A4/en active Pending
- 2021-10-08 JP JP2023521639A patent/JP2023545084A/ja active Pending
- 2021-10-08 AU AU2021358274A patent/AU2021358274A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196359A1 (en) | 2005-11-25 | 2010-08-05 | Shinichiro Kato | Human Monoclonal Antibody Human CD134 (Ox40) and Methods of Making and Using Same |
| WO2019229155A1 (en) | 2018-05-31 | 2019-12-05 | Glenmark Pharmceuticals S.A. | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders |
Non-Patent Citations (1)
| Title |
|---|
| NPL 1: Nakagawa et al. J. of Dermatological Science, 99: 82-89, 2020 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230383001A1 (en) | 2023-11-30 |
| CA3198414A1 (en) | 2022-04-14 |
| JP2023545084A (ja) | 2023-10-26 |
| TW202222343A (zh) | 2022-06-16 |
| AU2021358274A1 (en) | 2023-05-25 |
| WO2022075476A1 (en) | 2022-04-14 |
| EP4225371A4 (en) | 2024-11-20 |
| MX2023004113A (es) | 2023-06-29 |
| IL301935A (en) | 2023-06-01 |
| AU2021358274A9 (en) | 2024-05-30 |
| EP4225371A1 (en) | 2023-08-16 |
| CN116437955A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6637113B2 (ja) | Il−4rアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法 | |
| WO2022075476A1 (en) | Method for treating ox40 related disease | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| CN114173816A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| US20240059783A1 (en) | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| JP2022028788A (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| JP2024517796A (ja) | 抗baffr抗体を使用するループス腎炎の治療 | |
| JP2024518542A (ja) | 皮膚筋炎を処置する方法 | |
| JP2023504679A (ja) | インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法 | |
| JP2017193541A (ja) | 関節リウマチを治療するための医薬組成物 | |
| WO2025214333A1 (zh) | 抗tslp抗体治疗与tslp相关的炎症疾病的方法 | |
| WO2025106642A1 (en) | Methods for the treatment of thyroid eye disease | |
| CN121889429A (zh) | 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体 | |
| TW202041536A (zh) | 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法 | |
| CN108473576A (zh) | 用于治疗复发形式的多发性硬化的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| B11 | Application withdrawn |
Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |